Overview Dividends

(MEDP) Medpace Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58506Q1094

Clinical Trial Services, Regulatory Support, Data Management, Laboratory Analysis

MEDP EPS (Earnings per Share)

EPS Growth (3Y CAGR): 24.35%
EPS Trend (3Y Correlation): 90.0%

MEDP Revenue

Revenue Growth (3Y CAGR): 20.62%
Revenue Trend (3Y Correlation): 96.5%

Description: MEDP Medpace Holdings November 03, 2025

Medpace Holdings, Inc. (NASDAQ: MEDP) is a contract research organization that delivers end-to-end clinical development services-including trial design, central lab coordination, regulatory affairs, monitoring, data management, pharmacovigilance, and post-marketing support-to pharmaceutical, biotech, and medical-device clients across North America, Europe, and Asia. Its portfolio spans Phase I through Phase IV studies and encompasses ancillary capabilities such as bio-analytical labs, human pharmacology, imaging, and ECG read-outs.

Key recent metrics: FY 2023 revenue reached $1.06 billion, up ~7 % YoY, driven by higher enrollment volumes in oncology and rare-disease trials; the CRO industry is projected to grow at a CAGR of ~6 % through 2028, reflecting sustained biotech financing and accelerated drug pipelines; and Medpace’s operating margin improved to 12.5 % as it leveraged a “full-service” model to capture higher-value regulatory and data-analytics fees. A material driver of future performance is the U.S. FDA’s emphasis on real-world evidence, which could expand demand for Medpace’s post-marketing and pharmacovigilance services.

For a deeper, data-rich assessment of MEDP’s valuation relative to sector peers, you may find the analytics on ValueRay worth exploring.

MEDP Stock Overview

Market Cap in USD	16,732m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	2016-08-11

MEDP Stock Ratings

Growth Rating	80.2%
Fundamental	95.2%
Dividend Rating	-
Return 12m vs S&P 500	46.2%
Analyst Rating	3.33 of 5

MEDP Dividends

Currently no dividends paid

MEDP Growth Ratios

Growth Correlation 3m	96.3%
Growth Correlation 12m	43.1%
Growth Correlation 5y	87.5%
CAGR 5y	39.06%
CAGR/Max DD 3y (Calmar Ratio)	0.99
CAGR/Mean DD 3y (Pain Ratio)	2.96
Sharpe Ratio 12m	0.76
Alpha	56.19
Beta	1.408
Volatility	37.72%
Current Volume	235.5k
Average Volume 20d	296.9k
Stop Loss	564 (-4.3%)
Signal	1.34

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (433.0m TTM) > 0 and > 6% of Revenue (6% = 141.5m TTM)

FCFTA 0.40 (>2.0%) and ΔFCFTA 14.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -23.18% (prev -0.42%; Δ -22.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.41 (>3.0%) and CFO 711.2m > Net Income 433.0m (YES >=105%, WARN >=100%)

Net Debt (-141.4m) to EBITDA (520.8m) ratio: -0.27 <= 3.0 (WARN <= 3.5)

Current Ratio 0.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (29.7m) change vs 12m ago -7.41% (target <= -2.0% for YES)

Gross Margin 31.11% (prev 29.69%; Δ 1.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 122.9% (prev 99.37%; Δ 23.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 64.22 (EBITDA TTM 520.8m / Interest Expense TTM 7.88m) >= 6 (WARN >= 3)

Altman Z'' -1.81

(A) -0.31 = (Total Current Assets 737.3m - Total Current Liabilities 1.28b) / Total Assets 1.75b

(B) -0.34 = Retained Earnings (Balance) -596.2m / Total Assets 1.75b

(D) -0.41 = Book Value of Equity -601.6m / Total Liabilities 1.46b

Total Rating: -1.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 95.20

1. Piotroski 9.0pt = 4.0

2. FCF Yield 4.24% = 2.12

3. FCF Margin 29.83% = 7.46

4. Debt/Equity 0.49 = 2.38

5. Debt/Ebitda -0.27 = 2.50

6. ROIC - WACC (= 63.11)% = 12.50

7. RoE 91.88% = 2.50

8. Rev. Trend 96.49% = 7.24

9. EPS Trend 90.01% = 4.50

What is the price of MEDP shares?

As of November 09, 2025, the stock is trading at USD 589.15 with a total of 235,542 shares traded.
Over the past week, the price has changed by +0.72%, over one month by +10.77%, over three months by +37.40% and over the past year by +66.70%.

Is Medpace Holdings a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Medpace Holdings (NASDAQ:MEDP) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 95.20 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MEDP is around 686.52 USD . This means that MEDP is currently undervalued and has a potential upside of +16.53% (Margin of Safety).

Is MEDP a buy, sell or hold?

Medpace Holdings has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MEDP.

Strong Buy: 2
Buy: 0
Hold: 10
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MEDP price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	519.4	-11.8%
Analysts Target Price	519.4	-11.8%
ValueRay Target Price	783.6	33%

MEDP Fundamental Data Overview November 05, 2025

Market Cap USD = 16.73b (16.73b USD * 1.0 USD.USD)
P/E Trailing = 41.4818
P/E Forward = 36.2319
P/S = 7.0949
P/B = 87.3951
P/EG = 4.1374
Beta = 1.408
Revenue TTM = 2.36b USD
EBIT TTM = 506.3m USD
EBITDA TTM = 520.8m USD
Long Term Debt = 126.2m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 24.9m USD (from shortTermDebt, last quarter)
Debt = 144.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -141.4m USD (from netDebt column, last quarter)
Enterprise Value = 16.59b USD (16.73b + Debt 144.0m - CCE 285.4m)
Interest Coverage Ratio = 64.22 (Ebit TTM 506.3m / Interest Expense TTM 7.88m)
FCF Yield = 4.24% (FCF TTM 703.6m / Enterprise Value 16.59b)
FCF Margin = 29.83% (FCF TTM 703.6m / Revenue TTM 2.36b)
Net Margin = 18.36% (Net Income TTM 433.0m / Revenue TTM 2.36b)
Gross Margin = 31.11% ((Revenue TTM 2.36b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 29.84% (prev 29.84%)
Tobins Q-Ratio = 9.46 (Enterprise Value 16.59b / Total Assets 1.75b)
Interest Expense / Debt = 5.48% (Interest Expense 7.88m / Debt 144.0m)
Taxrate = 22.19% (31.7m / 142.8m)
NOPAT = 393.9m (EBIT 506.3m * (1 - 22.19%))
Current Ratio = 0.57 (Total Current Assets 737.3m / Total Current Liabilities 1.28b)
Debt / Equity = 0.49 (Debt 144.0m / totalStockholderEquity, last quarter 293.6m)
Debt / EBITDA = -0.27 (Net Debt -141.4m / EBITDA 520.8m)
Debt / FCF = -0.20 (Net Debt -141.4m / FCF TTM 703.6m)
Total Stockholder Equity = 471.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 24.70% (Net Income 433.0m / Total Assets 1.75b)
RoE = 91.88% (Net Income TTM 433.0m / Total Stockholder Equity 471.3m)
RoCE = 84.73% (EBIT 506.3m / Capital Employed (Equity 471.3m + L.T.Debt 126.2m))
RoIC = 74.25% (NOPAT 393.9m / Invested Capital 530.5m)
WACC = 11.14% (E(16.73b)/V(16.88b) * Re(11.20%) + D(144.0m)/V(16.88b) * Rd(5.48%) * (1-Tc(0.22)))
Discount Rate = 11.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -3.38%
[DCF Debug] Terminal Value 71.87% ; FCFE base≈636.4m ; Y1≈785.1m ; Y5≈1.34b
Fair Price DCF = 488.8 (DCF Value 13.77b / Shares Outstanding 28.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.01 | EPS CAGR: 24.35% | SUE: 1.41 | # QB: 1
Revenue Correlation: 96.49 | Revenue CAGR: 20.62% | SUE: 0.77 | # QB: 0

Additional Sources for MEDP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle